About

Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance. At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. About Sciomics GmbH Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. About Sciomics Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Sciomics has a robust immuno-proteomics platform for the development of protein biomarker panels as well as for the support of pre-clinical programs. On this basis we have established our own internal protein biomarker development pipeline and are offering CRO services for our customers in pharma and biotech. Currently, we are building a new venture bridging the gap between biomarker discovery, verification, and the introduction of our biomarker panels into the IVD market. The most advanced project focuses on scioAKI - a four-protein biomarker panel for an early and precise diagnosis of Acute Kidney Injury (AKI, for more details see asset scioAKI). Please get in touch if you are interested in partnering with us or investing in this endeavor. Our internal biomarker development pipeline, with the scioAKI project being our main program, is based on the scioDiscover platform. scioDiscover enables a robust combination of our proteomics data with AI-approaches for the definition of high-performance biomarker panels, both regarding sensitivity and specificity. As the platform is completely immuno-based, findings can be easily transferred to ELISA or similar tools for clinical routine use. In addition to our internal biomarker development pipeline, we offer CRO services based on our scioDiscover protein profiling platform and are welcoming R&D collaborations as well. Main applications are - the discovery and validation of novel biomarkers, - drug target screening, - the characterization of disease models, - the analysis of pathway activity as well as - mode-of-action studies. One of the key advantages in collaborating with us is our team of scientific experts that takes pride in custom-tailoring every project and consulting as well as supporting clients throughout the project. Our full-service ranges from discussing experimental designs to in-depth data analysis and yields a comprehensive study report. Fast and cost-efficient, Sciomics’ powerful high-content, high-throughput antibody array platform delivers reliable results that can be easily translated into validation or clinical assays. Thereby, we are a strong partner in generating value and opening new avenues for biomarker discovery, as well as target discovery and verification as well as preclinical drug development programs.